Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009

Health Affairs

Volumn 33, Issue 3, 2014, Pages 362-369

  Goldman, Dana P ^a   Juday, Timothy ^b   Seekins, Daniel ^c   Linthicum, Mark T ^d   Romley, John A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ABBVIE INC   (United States)

^c Virology external collaborations   (United States)

^d PRECISION HEALTH ECONOMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INFECTION PREVENTION; LEUKOCYTE COUNT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; UNITED STATES; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; EARLY INTERVENTION; ECONOMICS; EVIDENCE BASED MEDICINE; HIV INFECTIONS; MORTALITY; SOCIOECONOMICS; SURVIVAL ANALYSIS; TRANSMISSION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; INCIDENCE; LIFE EXPECTANCY; SURVIVAL ANALYSIS; UNITED STATES; VALUE OF LIFE;

EID: 84896886705     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.0830     Document Type: Article

References (55)

1. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington (DC): HHS; 2009 Dec 1 [cited 2014 Jan 15]. Available from: http://www.aidsinfo.nih.gov/ contentfiles/adultandadolescent gl001419.pdf
2. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Washington (DC): HHS; [last updated 2013 Feb 12; cited 2014 Jan 15]. Available from: http:// aidsinfo.nih.gov/contentfiles/ lvguidelines/AdultandAdolescentGL .pdf
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection: summary of new recommendations [Internet]. Geneva: WHO; 2013 [cited 2014 Jan 15]. Available from: http://www.who .int/entity/hiv/pub/guidelines/ arv2013/intro/summarynew recommendations.pdf
4. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26.
5. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group. Lancet. 1999;353(9169):2014-25.
6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-33.
7. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5): e5575.
8. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373(9672):1352-63.
9. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008; 197(8):1133-44.
10. Romley JA, Juday T, Solomon MD, Seekins D, Brookmeyer R, Goldman DP. Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996-2009. Health Aff (Millwood). 2014; 33(3):370-77.
11. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505.
12. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.
13. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18(1):81-8.
14. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778-89.
15. Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. Clin Infect Dis. 2013;56(12): 1789-96.
16. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392-400.
17. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57.
18. Eaton LA, Kalichman SC, O'Connell DA, Karchner WD. A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission. AIDS Care. 2009; 21(10):1279-88.
19. To access the Appendix, click on the Appendix link in the box to the right of the article online.
20. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med. 2000;160(8): 1134-40.
21. Barroso PF, Schechter M, Gupta P, Melo MF, Vieira M, Murta FC, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med. 2000;133:280-84.
22. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-53.
23. Fiore JR, Suligoi B, Saracino A, Di Stefano M, Bugarini R, Lepera A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17(15):2169-76.
24. Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis. 2008;197(7):1006-10.
25. Bachmann LH, Grimley DM, Waithaka Y, Desmond R, Saag MS, Hook EW 3rd. Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care. Sex Transm Dis. 2005;32(1):20-6.
26. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-9.
27. Longini IM Jr, Clark WS, Gardner LI, Brundage JF. The dynamics of CD4+ T-lymphocyte decline in HIVinfected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr. 1991;4(11): 1141-7.
28. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: U.S. HIV and AIDS cases reported through December 1995 [Internet]. Atlanta (GA): CDC; [cited 2014 Jan 16]. Available from: http:// www.cdc.gov/hiv/pdf/statistics_ hivsur72.pdf
29. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344(11):817-23.
30. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-9.
31. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
32. Lichtenberg FR. The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data. Expert Rev Pharmacoecon Outcomes Res. 2006; 6(4):425-36.
33. Arias E. United States life tables, 2000. Natl Vital Stat Rep. 2002; 51(3):1-38.
34. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: U.S. HIV and AIDS cases reported through December 2000 [Internet]. Atlanta (GA): CDC; [cited 2014 Jan 16]. Available from: http:// www.cdc.gov/hiv/topics/ surveillance/resources/reports/pdf/ hasr1202.pdf
35. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG.Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-42.
36. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. Washington (DC): Brookings Joint Center for Regulatory Studies; 2003 Jan.
37. Lipscomb J,Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB,Weinstein MC, editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996. p. 214-35.
38. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2011 [Internet]. Atlanta (GA): CDC; [last updated 2013 Jul 24; cited 2014 Jan 16]. (HIV Surveillance Report, Vol. 23). Available from: http://www.cdc.gov/hiv/ library/reports/surveillance/2011/ surveillance_report_vol_23.html
39. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: U.S. HIV and AIDS cases reported through December 1997 [Internet]. Atlanta (GA): CDC; [cited 2014 Jan 16]. Available from: http:// www.cdc.gov/hiv/pdf/statistics_ hivsur92.pdf
40. Miller M, Liao Y, Wagner M, Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis. 2008;35(7):696-702.
41. Cassels S, Menza TW, Goodreau SM, Golden MR. HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington. AIDS. 2009;23(18):2497-506.
42. Philip SS, Yu X, Donnell D, Vittinghoff E, Buchbinder S. Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort. PLoS One. 2010;5(9):e12662.
43. Gorbach PM, Weiss RE, Jeffries R, Javanbakht M, Drumright LN, Daar ES, et al. Behaviors of recently HIVinfected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr. 2011;56(2): 176-82.
44. Golden MR, Wood RW, Buskin SE, Fleming M, Harrington RD. Ongoing risk behavior among persons with HIV in medical care. AIDS Behav. 2007;11(5):726-35.
45. Zablotska IB, Imrie J, Prestage G, Crawford J, Rawstorne P, Grulich A, et al. Gay men's current practice of HIV seroconcordant unprotected anal intercourse: serosorting or seroguessing?. AIDS Care. 2009; 21(4):501-10.
46. Goldman DP, Zheng Y, Girosi F, Michaud PC, Olshansky SJ, Cutler D, et al. The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health. 2009;99(11):2096-101.
47. Rosen S. The value of changes in life expectancy. J Risk Uncertain. 1988; 1(3):285-304.
48. Murphy Kevin M, Topel Robert H. The value of health and longevity. J Polit Econ. 2006;114(5):871-904.
49. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7): e1001245.
50. Palmieri A, Mostovoy L, Akinbosoye O, Szychowski JA, Sehman ML, Matlin OS. Trends in first-year utilization costs of HIV medications. American Journal of Pharmacy Benefits [serial on the Internet]. 2012 Oct 17 [cited 2014 Jan 16]. Available from: http://www.ajmc .com/publications/ajpb/2012/ AJPB_SepOct2012/Trends-in-First-Year-Utilization-Costs-of-HIVMedications
51. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001; 344(11):824-31.
52. Hocqueloux L, Avettand-Fenoel V, Prazuck T, Melard A, Legac E, Niang M, et al. In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4=mm3 achieves better HIV-1 reservoirs' depletion (HIV-DNA) and T cell count restoration [Internet]. Paper presented at: 7th International AIDS Society Conference on HIV; 2013 Jun 30-Jul 3; Kuala Lumpur, Malaysia.
53. Jena AB. Balancing disease eradication with the emergence of multidrug-resistant HIV in test-and-treat policies. Clin Infect Dis. 2013; 56(12):1797N9.
54. Ryan GW, Bloom EW, Lowsky D, Linthicum MT, Juday T, Rosenblatt L, et al. Data-driven decision-making tools to improve public resource allocation for care and prevention in HIV/AIDS. Health Aff (Millwood). 2014;33(3):410-17.
55. Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002; 162(21):2478-86.